Powell B J, Campbell J L, Landon J F, Liskow B I, Thomas H M, Nickel E J, Dale T M, Penick E C, Samuelson S D, Lacoursiere R B
Kansas City Veterans Administration Medical Center (151), Kansas City 64128, USA.
Alcohol Clin Exp Res. 1995 Apr;19(2):462-8. doi: 10.1111/j.1530-0277.1995.tb01532.x.
This double-blind, placebo-controlled, 6-month follow-up treatment study investigated the efficacy of bromocriptine and nortriptyline in attenuating drinking behavior and psychiatric symptoms in 216 male alcoholic patients subtyped by comorbid psychiatric disorder(s). Three well-defined subtypes were examined: alcoholism only, alcoholism + affective/anxiety disorder, and alcoholism + antisocial personality disorder. It was hypothesized that both medications would relieve negative affective symptoms associated with alcohol use and would be particularly effective for the affective/anxiety subgroup. Contrary to our predictions, the only significant effects found were with the antisocial personality disorder patients who were receiving nortriptyline. One interpretation of the results was that nortriptyline may have reduced impulsive drinking in the antisocial personality disorder subgroup by actions on serotonergic neurotransmission.
这项双盲、安慰剂对照、为期6个月的随访治疗研究，调查了溴隐亭和去甲替林对216名根据共病精神障碍进行亚型分类的男性酒精成瘾患者饮酒行为和精神症状的缓解效果。研究考察了三种明确界定的亚型：单纯酒精成瘾、酒精成瘾+情感/焦虑障碍、酒精成瘾+反社会人格障碍。研究假设这两种药物都能缓解与饮酒相关的负面情感症状，并且对情感/焦虑亚组特别有效。与我们的预测相反，唯一发现的显著效果出现在接受去甲替林治疗的反社会人格障碍患者中。对结果的一种解释是，去甲替林可能通过作用于血清素能神经传递，减少了反社会人格障碍亚组中的冲动饮酒行为。
